Internal Medicine, Rheumatology · Catonsville, MD
NPI
1528155439
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
700 Geipe Rd, Suite 200
Catonsville, MD, 21228
Phone (410) 744-0661
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
226,442 services
Medicare patients, 2024
680
Average age 71
Drug cost, 2024
$4.5M
2,940 prescriptions
Company payments, 2025
$1,130
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeffrey T Landis was code J3262 (injection, tocilizumab, 1 mg), 87,640 times for 19 patients. In total Jeffrey T Landis billed 226,442 services in 90 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 87,640 | 19 | $4.71 | $412K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 32,656 | 39 | $9.07 | $296K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 10,950 | 168 | $0.10 | $1,105 |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 9,000 | 14 | $33.85 | $305K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,290 | 15 | $24.95 | $107K |
| J9312 Injection, rituximab, 10 mg | Office | 2,990 | 13 | $61.28 | $183K |
| J0897 Injection, denosumab, 1 mg | Office | 1,620 | 20 | $20.44 | $33K |
| 36415 Venipuncture Blood Collection | Office | 1,606 | 558 | $4.88 | $7,841 |
| 80053 Clinical Chemistry | Office | 1,549 | 547 | $10.31 | $16K |
| 85025 Blood Count | Office | 1,523 | 541 | $7.58 | $12K |
| 86140 Clinical Chemistry | Office | 1,412 | 475 | $5.06 | $7,145 |
| 85652 Clinical Chemistry | Office | 1,406 | 472 | $2.64 | $3,711 |
| 99214 Office E&M - Established | Office | 1,392 | 497 | $98.64 | $137K |
| 86235 Immunoassay | Office | 960 | 118 | $17.57 | $17K |
| 96413 Chemotherapy Administration | Office | 821 | 135 | $110.11 | $90K |
By year: 2022 $2.4M for 115,322 services; 2023 $2.9M for 176,388 services; 2024 $3.2M for 226,442 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,606 | 558 | $4.88 | $7,841 |
| 80053 Clinical Chemistry | 1,549 | 547 | $10.31 | $16K |
| 85025 Blood Count | 1,523 | 541 | $7.58 | $12K |
| 86140 Clinical Chemistry | 1,412 | 475 | $5.06 | $7,145 |
| 85652 Clinical Chemistry | 1,406 | 472 | $2.64 | $3,711 |
| 86235 Immunoassay | 960 | 118 | $17.57 | $17K |
| 86160 Immunoassay | 373 | 86 | $11.76 | $4,386 |
| 86146 Immunoassay | 361 | 119 | $24.94 | $9,003 |
| 86147 Immunoassay | 360 | 118 | $24.94 | $8,978 |
| 83516 Immunoassay | 269 | 132 | $11.30 | $3,040 |
Medicare prescription drug claims, 2024
In 2024, the drug Jeffrey T Landis prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 544 prescriptions and refills. In total Jeffrey T Landis wrote 2,940 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 544 | 1,369 | 165 | $31K |
| Methotrexate Methotrexate Sodium | 326 | 764 | 100 | $9,394 |
| Gabapentin Generic | 203 | 346 | 55 | $3,648 |
| Prednisone Generic | 166 | 185 | 95 | $856 |
| Humira(Cf) Pen Adalimumab | 139 | 139 | 16 | $1.0M |
| Allopurinol Generic | 133 | 367 | 46 | $2,343 |
| Leflunomide Generic | 120 | 287 | 37 | $7,266 |
| Pregabalin Generic | 111 | 155 | 27 | $6,145 |
| Cyclobenzaprine Hcl Generic | 73 | 121 | 27 | $677 |
| Duloxetine Hcl Generic | 69 | 170 | 26 | $1,588 |
| Celecoxib Generic | 65 | 105 | 22 | $3,016 |
| Enbrel Sureclick Etanercept | 62 | 64 | 12 | $480K |
| Baclofen Generic | 60 | 88 | 18 | $1,227 |
| Xeljanz Xr Tofacitinib Citrate | 59 | 69 | 12 | $405K |
| Colchicine Generic | 59 | 127 | 19 | $5,616 |
Brand drugs: 622 claims; generic drugs: 2,318 claims; opioid claims: 65.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeffrey T Landis $1,130 ($1,130 in general payments such as food, travel and fees) from 11 companies. The largest payer was Abbvie Inc. with $337.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 26 | $337 |
| Amgen Inc. AMGN | 15 | $247 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $116 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $103 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $96.11 |
| Pfizer Inc. PFE | 4 | $82.53 |
| Aurinia Pharma U.S., Inc. AUPH | 2 | $57.59 |
| Sandoz Inc. SDZ.SW | 1 | $32.17 |
| Genzyme Corporation SNY | 1 | $24.29 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $21.05 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.